Paraguay Medical Device Registration 2026: Stability Study Requirements and Shelf Life Declaration

1. Key takeaways

1. Article 6, item f) requires the submission of stability studies (Estudios de Estabilidad) in the situations where they apply.
2. The operating instructions tie three platform fields to the stability evidence: storage condition, storage and transport condition, and shelf life (Plazo de Vida Útil). All three must be declared according to the technical report of the manufacturer, supported by documents issued by the manufacturer, such as stability studies and aging tests.
3. The definitions chapter of the resolution, item 21, defines the batch number or serial number as the alphabetic or numeric marking that gives the product traceability, justified by the uniformity of the products of the same production or sterilization cycle; stability conclusions rest precisely on that uniformity.
4. The renewal list (Article 12, item f)) requires stability studies again, making the obligation recurring. For products whose shelf life is short, the recurrence is active rather than theoretical: the evidence supporting the original declaration may be several generations old by the time the renewal dossier is assembled, and fresh studies may be the only way to keep the three fields defensible.

2. Legal basis

The resolution supplies both the requirement and the traceability concept behind it, while page 5 of the operating instructions names the exact platform fields that the stability evidence must support: the conservation condition field and the useful life period field, alongside the transport condition declaration. The three fields are also the fields most likely to be read against the physical product during oversight, since inspectors compare labelled storage instructions with the registration record. Consistency at submission therefore protects the certificate for its whole life, not only during the initial evaluation. Because the shelf life field anchors the stability evidence, the declared value should never exceed what the submitted studies can defend.

3. Expert insights

Insight one: the stability evidence is not a report handed over in isolation; it supports three specific fields. The operating instructions point the declaration basis of the storage condition, the transport condition and the shelf life fields directly to stability studies and aging tests. The value of the evidence therefore lies in being traceable to specific fields, not merely in existing somewhere in the dossier. If any of the three fields disagrees with the conclusion of the underlying report during review, the discrepancy will be raised as a deficiency and consume a rectification round. A cross-reference table between the report conclusions and the three fields is the simplest safeguard. Building that table during dossier assembly takes little effort, and it converts the review of the three fields from an open question into a closed comparison that the applicant has already performed.

Insight two: the phrase where applicable grants flexibility, but it also leaves interpretive room. Item f) uses the expression cuando corresponda, meaning where it applies. Which products fall inside that scope depends on the product characteristics and on the shelf life claim. For products that declare a shelf life, including those with sterile barriers, reagents and drug-device combinations, stability evidence is in practice a mandatory submission (practical estimate: derived from the field requirements). Treating the flexibility as an exemption without a documented rationale is a common and avoidable mistake. A short written rationale for products excluded from the scope, signed by the regulatory function, gives the exclusion a defensible basis if the reviewer asks why no study was submitted.

Insight three: the recurring renewal requirement turns the shelf life decision into a long-term commitment. The registration certificate is valid for 10 years, but product shelf lives are usually far shorter. Because stability studies must be submitted again at renewal, any later change to the declared shelf life is a change matter that must be classified and processed under Article 13. The shelf life set at first submission therefore becomes the baseline for the entire decade that follows, which is why the first declaration deserves more analysis than its apparent simplicity suggests. Plan the renewal submission at the moment of the first declaration: choose a shelf life the data can support for a full registration cycle, and note when fresh studies will be needed before the renewal dossier is assembled.

4. Practical recommendations

1. Decide the product shelf life and the storage and transport conditions before submission, and derive backwards which stability or aging test data are needed to support them, and record the derivation in a short memo that links the product claim to the test conditions.
2. Align the conclusions of the stability report with the three platform fields one by one, and record the alignment in a comparison table kept with the dossier.
3. Build sufficient margin into the shelf life declared at first submission, so that the declaration does not need frequent change submissions later, since every later extension of the shelf life is a change submission with its own evaluation.
4. Add the stability evidence to the annual renewal ledger required by Article 12, item f), and track its expiry alongside the other recurring documents, so the evidence is refreshed before the renewal window opens 120 business days before expiry.
5. Where a product is excluded from the scope of item f), record the exclusion rationale in the dossier, so the reviewer sees a documented decision rather than a silent omission.

5. Verification checklist

• □ Determination made on whether the product falls within the where applicable scope
• □ Stability study or aging test report obtained
• □ Storage condition, transport condition and shelf life fields consistent with the report conclusions
• □ Sufficient margin built into the shelf life declared at first submission
• □ Renewal ledger includes Article 12, item f)

Regulatory information verified as of October 29, 2026.

GRZAN provides registration and conformity support in Paraguay for medical device manufacturers, importers and authorized representatives, including stability evidence planning and shelf life change management. For assistance, contact info@grzanglobal.com.